Apexigen Announces New Collaboration With UCSF
-- Clinical Trial Collaboration to Evaluate Apexigen's Immune Activating Antibody APX005M in Combination with Multimodality Treatment of Resectable Esophageal and Gastro-Esophageal Junction Cancers --
SAN CARLOS, Calif., Oct. 25, 2017 /PRNewswire/ -- Apexigen, a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the initiation of patient enrollment in a Phase 2 clinical trial in collaboration with the University of California, San Francisco (UCSF). This trial is designed to evaluate Apexigen's CD40 agonistic antibody, APX005M, in combination with multimodal treatment (chemotherapy and radiation therapy) in patients with resectable esophageal and gastro-esophageal junction cancers.
"APX005M has demonstrated robust immune activation with a good safety profile in cancer patients. There is very strong scientific rationale to expect synergistic benefits in treating patients with esophageal or gastro-esophageal junction cancers with APX005M in combination with current standard-of-care therapies for these types of cancers," said Ovid Trifan, M.D., Ph.D., Chief Medical Officer at Apexigen. "We are eager to collaborate with UCSF to explore ways to improve the treatment of this disease through stimulating patients' anti-cancer immune responses."
Andrew Ko, M.D., Professor, Department of Medicine (Hematology/Oncology) UCSF, is the Principal Investigator of this new clinical trial. Additional information on this clinical trial is available at www.clinicaltrials.gov (identifier: NCT03165994).
About Apexigen, Inc.
SOURCE Apexigen, Inc.